Browsing Tag
CATALYST trial
2 posts
Corcept Therapeutics (NASDAQ: CORT) puts resistant hypertension in the cortisol spotlight with new MOMENTUM trial data
Corcept Therapeutics says 27.3% of resistant hypertension patients may have hypercortisolism. Read what the MOMENTUM data could mean next.
CATALYST clinical trial : FDA approves Abbott’s trial of Amplatzer Amulet device in AF
Abbott has been granted approval from the US Food and Drug Administration (FDA) for the CATALYST clinical trial…